A traditional medicine, respiratory detox shot (RDS), inhibits the infection of SARS-CoV, SARS-CoV-2, and the influenza A virus in vitro
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Background
The ongoing global pandemic of coronavirus disease 2019 (COVID-19) has resulted in the infection of over 128 million people and has caused over 2.8 million deaths as of April 2021 in more than 220 countries and territories. Currently, there is no effective treatment for COVID-19 to reduce mortality. We investigated the potential anti-coronavirus activities from an oral liquid of traditional medicine, Respiratory Detox Shot (RDS), which contains mostly herbal ingredients traditionally used to manage lung diseases.
Results
Here we report that RDS inhibited the infection of target cells by lenti-SARS-CoV, lenti-SARS-CoV-2, and hybrid alphavirus-SARS-CoV-2 (Ha-CoV-2) pseudoviruses, and by infectious SARS-CoV-2 and derived Ha-CoV-2 variants including B.1.1.7, B.1.351, P.1, B.1.429, B.1.2, B.1.494, B.1.1.207, B.1.258, and B.1.1.298. We further demonstrated that RDS directly inactivates the infectivity of SARS-CoV-2 virus particles. In addition, we found that RDS can also block the infection of target cells by Influenza A virus.
Conclusions
These results suggest that RDS may broadly inhibit the infection of respiratory viruses.
Article activity feed
-
-
-
SciScore for 10.1101/2020.12.10.420489: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Cells and cell culture: HEK293T (ATCC, Manassas, VA), MDCK (ATCC, Manassas, VA), Vero E6 (ATCC, Manassas, VA), and A549(ACE2) (a gift from Virongy, Manassas, VA) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Thermo Fisher Scientific) containing 10% heat-inactivated FBS and 1x penicillin-streptomycin (Thermo Fisher A549suggested: NoneBriefly, for the production of GFP reporter lentiviral pseudovirus, HEK293T cells were … SciScore for 10.1101/2020.12.10.420489: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Cells and cell culture: HEK293T (ATCC, Manassas, VA), MDCK (ATCC, Manassas, VA), Vero E6 (ATCC, Manassas, VA), and A549(ACE2) (a gift from Virongy, Manassas, VA) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Thermo Fisher Scientific) containing 10% heat-inactivated FBS and 1x penicillin-streptomycin (Thermo Fisher A549suggested: NoneBriefly, for the production of GFP reporter lentiviral pseudovirus, HEK293T cells were cotransfected with the vector expressing the SARS-CoV S protein or the SARS-CoV-2 S protein, pCMVΔR8.2, and pLKO. HEK293Tsuggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)Virus was harvested from the supernatant and the vial titers were determined by plaque assay in Vero cell monolayers grown in 12-well plates. Verosuggested: NoneTwo hundred microliters of each dilution were then adsorbed onto triplicate wells of Vero E6 cell monolayers for 1 hour. Vero E6suggested: RRID:CVCL_XD71)Drug toxicity on MDCK cells was quantified using Cell Proliferation Kit I (MTT) (Sigma) and the protocol suggested by the manufacturer. MDCKsuggested: CLS Cat# 602280/p823_MDCK_(NBL-2, RRID:CVCL_0422)Software and Algorithms Sentences Resources GFP expression was quantified by flow cytometer (FACSCalibur, BD Biosciences) FACSCalibursuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-